Today, monoclonal antibodies are considered as one of the most important therapeutic molecules in the world, which is used in diseases such as autoimmune diseases, cardiovascular diseases, infectious diseases, inflammation and cancer, and has created a multi-billion dollar industry. Currently, 22 monoclonal antibodies have been approved by the FDA and are available in the US and many other countries and have shown a growth rate of 35% so far. Among these antibodies are antibodies such as Rituximab, Rituximab, Bevacizumab, Infliximab, Panitumumab and Cetuximab, all of which are important drugs.
Cetuximab is a chimeric antibody (human / mouse) that contains the human IgG1 constant region and the variable moiety belonging to the mouse antibody. This monoclonal antibody binds to the EGFR epidermal growth factor receptor and inhibits this receptor and prevents EGF binding to it, which is used in the treatment of metastatic colorectal cancer, lung cancer and head and neck carcinoma in the absence of mutations in the kras gene. Takes. The role of intracellular EGFR signaling in colorectal cancer has been well established and therefore its inhibition has important effects on this disease.
In the last decade, two therapeutic strategies have been developed to inhibit EGFR, the use of monoclonal antibodies and the use of small molecules that inhibit tyrosine kinase activity.
In the strategy of using antibodies, Cetuximab by its competitive binding to the second extracellular EGFR prevents the binding of TGF and EGF, which does not create another intracellular signal cascade and inhibits the proliferation of cancer cells.
Rituximab is a type of drug known as a biological treatment that can reduce inflammation and damage to the joints. Also known as MabThera, Rixathon, Ruxience and Truxima.
Normally, the immune system produces inflammation to protect the body against infections. But in some cases, a group of immune system cells called B cells cause unnecessary inflammation that damages healthy body tissue. Rituximab reduces inflammation, pain, swelling and joint damage by reducing the number of these B cells.
Bevacizumab is a cancer drug and is also known as Avastin.
Bevacizumab targets a cancer cell protein called vascular endothelial growth factor (VEGF). This protein in cancer cells helps blood vessels to grow, so they can get food and oxygen from the blood. All cancer cells need blood to survive and grow. Bevacizumab blocks this protein and prevents blood vessels from growing around the cancer cells, so they cannot grow. Therapies that interfere with blood flow are called anti-angiogenic therapies.
In recent years, favorable work on the production of these items, such as Cetuximab and several other items of monoclonal antibodies, has been done by researchers and domestic companies, and promising results have been obtained. Meanwhile, the experienced scientific team of this research group made many efforts in this regard, which eventually, with God’s help, led to the acquisition of technology for making monoclonal antibodies, and now the group intends to produce according to this ability. This drug in the country.